Yu Xin-Ning, Wu Hua-Tao, Wu Bing-Xuan, Zhi Shu-Feng, Lan Yang-Zheng, Chen Wen-Jia, Liu Jing
The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China.
Department of General Surgery, First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China.
World J Gastrointest Oncol. 2025 Jul 15;17(7):107681. doi: 10.4251/wjgo.v17.i7.107681.
Colorectal cancer (CRC) ranks as the third most common cancer globally and the second leading cause of cancer-related deaths, representing a significant health burden. Despite advancements in traditional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, these approaches still face challenges, including high costs, limited efficacy, and drug resistance. Drug repurposing has emerged as a promising strategy for CRC treatment, offering advantages with reduced development timelines, lower costs, and improved drug accessibility. This review explores drug repurposing strategies for CRC, supported by multidisciplinary technologies, and discusses the current challenges in the field.
结直肠癌（CRC）是全球第三大常见癌症，也是癌症相关死亡的第二大主要原因，构成了重大的健康负担。尽管手术、化疗、靶向治疗和免疫治疗等传统治疗方法取得了进展，但这些方法仍面临挑战，包括成本高、疗效有限和耐药性。药物重新利用已成为一种有前景的结直肠癌治疗策略，具有缩短开发时间、降低成本和提高药物可及性等优势。本综述探讨了多学科技术支持的结直肠癌药物重新利用策略，并讨论了该领域当前面临的挑战。
